SARS-Cov-2 Spike Protein Antibody Titers In Cord Blood After Vaccination Against Covid-19 During Pregnancy

N. Kintraia, P. Machavariani, N. Gogokhia, K. Grigalashvili, N. Metskhvarishvili, M. Rizhvadze, B. Japaridze, N. Khotivari, N. Pkhaladze, E. Shvelashvili, L. Barbakadze, K. Chichua, K. Mikaberidze, M. Merkviladze


In the early months of the COVID-19 pandemic, pregnant patients faced uncertain risks associated with severe acute respiratory syndrome SARS-CoV-2 viral infection. Aim of the study was to determine the titer of specific maternal and umbilical cord antibodies against SARS-CoV-2 viral protein S receptor domain after maternal antenatal vaccination. The paper presents preliminary results of the study proceeded in the department. 13 patients vaccinated during different gestational age have been included in the study. All patients participating in this study were vaccinated with two doses of BNT162b2 mRNA COVID-19 vaccine between the 4 to 31 week of gestation. The in vitro qualitative and quantitative determination of antibodies against SARS-CoV-2 viral protein S receptor domain in serum samples was performed by using an electrochemiluminescence immunoassay.  Study results demonstrated that, vaccination against SARS-Cov-2 viral infection during pregnancy is accompanied with adequate production of antibodies that probably may defense neonates from severe infection at least within 6 month of life. Study has revealed positive correlation between time interval of vaccination and delivery for the presence of high titers of SARS-Cov-2 viral protein S receptor domain antibodies in neonatal cord blood, which may allow future determination of the optimal timing of COVID-19 vaccination in pregnant women although this problem need more future studies.


Covid-19, pregnancy, vaccination, immunity.

Full Text:



Lokken EM, Walker CL, Delaney S, et al. Clinical characteristics of 46 pregnant women withasevereacuterespiratorysyndromecoro- 2 infection in Washington State. Am J ObstetGynecol2020;223:911.e1–14.

Zambrano LD, Ellington S, Strid P, et al. Up- date: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69: 1641–7.

Knight M, Bunch K, Vousden N, et al. Char- acteristics and outcomes of pregnant women admittedtohospitalwithconfirmedSARS-CoV- 2 infection in UK: national population based cohortstudy.BMJ2020;369:m2107

Schwartz,D.A.;Graham,A.L.PotentialMaternalandInfantOutcomesfrom(Wuhan)Coronavirus2019-nCoVInfectingPregnant Women:LessonsfromSARS,MERS,andOtherHumanCoronavirusInfections. Viruses2020,12,194.

Pettirosso,E.;Giles,M.;Cole,S.;Rees,M.COVID-19andpregnancy: Areviewofclinicalcharacteristics,obstetricoutcomesand verticaltransmission. Aust. NewZealandJ.Obstet. Gynaecol. 2020,60,640–659. [CrossRef]

Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini,C.;etal. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615.



EfficacyandSafetyofthemRNA-1273SARS-CoV-2Vaccine. N.Engl. J.Med. 2021,384,403–416. [CrossRef][PubMed]

Sadoff, J.; Gray, G.; Vandebosch, A.; Cardenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.;

Spiessens,B.;etal. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021, 384,

–2201. [CrossRef]

Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S.; Kovyrshina, A.V.;

Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boostCOVID-19vaccine: Aninterimanalysisofarandomisedcontrolledphase3trialinRussia. Lancet2021,397,671–681.


Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.;

Bhorat,Q.E.;etal.SafetyandefficacyoftheChAdOx1nCoV-19vaccine(AZD1222)againstSARS-CoV-2: Aninterimanalysisof

fourrandomisedcontrolledtrialsinBrazil,SouthAfrica,andtheUK.Lancet2021,397,99–111. [CrossRef]

Maykin,M.M.;Heuser,C.;Feltovich,H.PregnantpeopledeservetheprotectionofferedbySARS-CoV-2vaccines. Vaccine2021,

,171–172. [CrossRef]

Craig,A.M.;Hughes,B.L.;Swamy,G.K.Coronavirusdisease2019vaccinesinpregnancy. Am. J.Obstet. Gynecol. MFM2021,3,


Royal College of Obstetricians and Gynaecologists. Updated Advice on COVID-19 Vaccination in Pregnancy and Women WhoAreBreastfeeding. Availableonline: pregnancy-and-women-who-are-breastfeeding/(accessedon6April2021).

Abu Raya, B.; Edwards, K.M.; Scheifele, D.W.; Halperin, S.A. Pertussis and influenza immunisation during pregnancy: A landscapereview. LancetInfect. Dis. 2017,17,e209–e222.

. L’Huillier, A.G.; Meyer, B.; Andrey, D.O.; Arm-Vernez, I.; Baggio, S.; Didierlaurent, A.; Eberhardt, C.S.; Eckerle, I.; Grasset- Salomon, C.; Huttner, A.; et al. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital. workers: Aprospectivelongitudinalstudy. Clin. Microbiol. Infect. 2021,27,784.e1–784.e8.



  • There are currently no refbacks.

Copyright (c) 2022 N. Kintraia, P. Machavariani, N. Gogokhia

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.